BDAZ, it seems to me that slide 14 suggests that the quality control of the sample patients is on target in terms of the sample quality (at least in terms of averages) criteria based on the 90% of the sample enrolled in the trial to date.

If correct it seems to me to suggest that the company running the trial is meeting the required quality standards required by the design of the trial.

The reason I point this out is that I recall some trial quality problems in the ASSURE trial and I think these problems related to 1 or 2 test group patients that had no apabetalone in there blood samples after the trial. Of course this problem could still occur in the BoM trial even though the sample is well recruited I assume.

These things are always far more complicated than I can understand. For example, if these criteria are not reasonably balanced within subgroups the findings could be impacted I assume.

Anyway my simple point is that slide 14 seems reassuring to me.

GLTA

Toinv